DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP 1.6 MG
DOPAMINE HYDROCHLORIDE : 1.6 MG DEXTROSE : 50 MG · DIN 00761826 · BAXTER CORPORATION
Health Canada status: MARKETED
What is DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP?
DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP 1.6 MG contains DOPAMINE HYDROCHLORIDE : 1.6 MG DEXTROSE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00761826, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Dec-1990. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP used for?
Dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Where appropriate, restoration of blood volume with a suitable plasma expander, or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. Patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. The shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00761826 |
|---|---|
| Brand name | DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP |
| Generic / active ingredient | DOPAMINE HYDROCHLORIDE : 1.6 MG DEXTROSE : 50 MG |
| Manufacturer | BAXTER CORPORATION |
| Strength | 1.6 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C01CA04 DOPAMINE |
| AHFS class | 12:12.08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1990 |
| Original market date | 1990-12-31 00:00:00 |
How is it stored and handled?
It is recommended the product be stored at room temperature (15-25°C): brief exposure up to 40°C does not adversely affect the product. Avoid excessive heat. Protect from light and freezing.
How is it supplied?
Dopamine Hydrochloride and 5% Dextrose Injection, USP in VIAFLEX plastic container is available in different sizes and concentrations as listed in Table 1.
What can be used instead?
Other Canadian products sharing ATC code C01CA04 DOPAMINE. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP | 50 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761850 |
| DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP | 3.2 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761834 |
| DOPAMINE HCL INJ 4% | 40 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00423823 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00619701 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00619698 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00782394 |
| INTROPIN INJECTION 40MG/ML | 40 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01914014 |
Who else supplies DOPAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOPAMINE appears in 16 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.